Active	Status	Sponsor type	Region	Phase	Filter
7 Active 4 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FALCHERO, Lionel
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies	Recruiting	4	500	Europe	Bio-bank repository, Quality of Life (QoL), G-Code	Groupe Francais De Pneumo-Cancerologie	Non Small Cell Lung Cancer, Lung Cancer	08/26	08/28
API-CAT, NCT03692065 / 2017-003342-25: STUDY for APIxaban Cancer Associated Thrombosis	Completed	3	1766	Europe, Canada	Apixaban 5 MG, Apixaban 2.5 MG	Assistance Publique - Hôpitaux de Paris, Bristol-Myers Squibb	Cancer-associated Thrombosis	09/24	10/24
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %	Active, not recruiting	3	349	Europe	Pembrolizumab, Pembrolizumab and Chemotherapy drugs	University Hospital, Brest, Groupe Français de Pneumo-Cancérologie	Non-small-cell Lung Cancer	12/25	12/25
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC	Recruiting	2	30	Europe	Repotrectinib	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon	NSCLC Stage IV, NSCLC, Stage III	09/31	09/31
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)	Recruiting	2	67	Europe	Carboplatin + Paclitaxel + Durvalumab	Intergroupe Francophone de Cancerologie Thoracique	Small Cell Lung Cancer Extensive Stage	02/26	02/28
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax	Recruiting	2	550	Europe	Durvalumab	UNICANCER, AstraZeneca	Small Cell Lung Carcinoma	01/27	03/29
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC	Active, not recruiting	N/A	413	Europe	Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)	Groupe Francais De Pneumo-Cancerologie, AstraZeneca	Non-Small Cell Lung Cancer	06/27	06/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FALCHERO, Lionel
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies	Recruiting	4	500	Europe	Bio-bank repository, Quality of Life (QoL), G-Code	Groupe Francais De Pneumo-Cancerologie	Non Small Cell Lung Cancer, Lung Cancer	08/26	08/28
API-CAT, NCT03692065 / 2017-003342-25: STUDY for APIxaban Cancer Associated Thrombosis	Completed	3	1766	Europe, Canada	Apixaban 5 MG, Apixaban 2.5 MG	Assistance Publique - Hôpitaux de Paris, Bristol-Myers Squibb	Cancer-associated Thrombosis	09/24	10/24
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %	Active, not recruiting	3	349	Europe	Pembrolizumab, Pembrolizumab and Chemotherapy drugs	University Hospital, Brest, Groupe Français de Pneumo-Cancérologie	Non-small-cell Lung Cancer	12/25	12/25
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC	Recruiting	2	30	Europe	Repotrectinib	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon	NSCLC Stage IV, NSCLC, Stage III	09/31	09/31
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)	Recruiting	2	67	Europe	Carboplatin + Paclitaxel + Durvalumab	Intergroupe Francophone de Cancerologie Thoracique	Small Cell Lung Cancer Extensive Stage	02/26	02/28
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax	Recruiting	2	550	Europe	Durvalumab	UNICANCER, AstraZeneca	Small Cell Lung Carcinoma	01/27	03/29
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC	Active, not recruiting	N/A	413	Europe	Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)	Groupe Francais De Pneumo-Cancerologie, AstraZeneca	Non-Small Cell Lung Cancer	06/27	06/27